{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:08:19Z","timestamp":1793192899017,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3098-7","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T15:35:02Z","timestamp":1486654502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Enhanced and long term immunogenicity of a Her-2\/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide"],"prefix":"10.1186","volume":"17","author":[{"given":"Joshua","family":"Tobias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Jasinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Baier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Ede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Wiedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"3098_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235:177\u201382.","journal-title":"Science"},{"key":"3098_CR2","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1007\/s00018-004-4277-7","volume":"61","author":"S M\u00e9nard","year":"2004","unstructured":"M\u00e9nard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2\/neu in tumor progression and therapy. Cell Mol Life Sci. 2004;61:2965\u201378.","journal-title":"Cell Mol Life Sci"},{"key":"3098_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-013-2410-8","volume":"138","author":"U Wiedermann","year":"2013","unstructured":"Wiedermann U, Davis AB, Zielinski CC. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2\/neu peptide vaccines. Breast Cancer Res Treat. 2013;138:1\u201312.","journal-title":"Breast Cancer Res Treat"},{"key":"3098_CR4","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.vaccine.2005.01.007","volume":"23","author":"CY Wang","year":"2005","unstructured":"Wang CY, Walfield AM. Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. Vaccine. 2005;23:2049\u201356.","journal-title":"Vaccine"},{"key":"3098_CR5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.1383","volume":"9","author":"DR Flower","year":"2013","unstructured":"Flower DR. Designing immunogenic peptides. Nat Chem Biol. 2013;9:749\u201353.","journal-title":"Nat Chem Biol"},{"key":"3098_CR6","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ijc.11485","volume":"107","author":"J Jasinska","year":"2003","unstructured":"Jasinska J, Wagner S, Radauer C, Sedivy R, Brodowicz T, Wiltschke C, et al. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2\/neu. Int J Cancer. 2003;107:976\u201383.","journal-title":"Int J Cancer"},{"key":"3098_CR7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10549-006-9469-4","volume":"106","author":"S Wagner","year":"2007","unstructured":"Wagner S, Jasinska J, Breiteneder H, Kundi M, Pehamberger H, Scheiner O, et al. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2\/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat. 2007;106:29\u201338.","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"3098_CR8","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.vaccine.2005.04.026","volume":"23","author":"A Huckriede","year":"2005","unstructured":"Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, et al. The virosome concept for influenza vaccines. Vaccine. 2005;23 Suppl 1:S26\u201338.","journal-title":"Vaccine"},{"key":"3098_CR9","doi-asserted-by":"crossref","unstructured":"Moser C, M\u00fcller M, Kaeser MD, Weydemann U, Amacker M. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines. 2013;12:779\u201391.","DOI":"10.1586\/14760584.2013.811195"},{"key":"3098_CR10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10549-009-0666-9","volume":"119","author":"U Wiedermann","year":"2009","unstructured":"Wiedermann U, Wiltschke C, Jasinska J, Kundi M, Zurbriggen R, Garner-Spitzer E, et al. A virosomal formulated Her-2\/neu multi peptide vaccine induces Her-2\/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat. 2009;119:673\u201383.","journal-title":"Breast Cancer Res Treat"},{"key":"3098_CR11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","volume":"17","author":"CL Slingluff","year":"2011","unstructured":"Slingluff CL. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 2011;17:343\u201350.","journal-title":"Cancer J"},{"key":"3098_CR12","unstructured":"Pevion Biotech AG, Kammer A, Amacker M, Zurbriggen R. Multiepitope vaccine for Her2\/neu-associated cancers. International Publication No. WO 2011\/020604 A1. 2011. World Intellectual Property Organization, International Bureau, WIPO\/OMPI, Geneva."},{"key":"3098_CR13","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1073\/pnas.1201964109","volume":"109","author":"E Malito","year":"2012","unstructured":"Malito E, Bursulaya B, Chen C, Lo Surdo P, Picchianti M, Balducci E, et al. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc Natl Acad Sci U S A. 2012;109:5229\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3098_CR14","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1016\/j.vaccine.2010.04.072","volume":"28","author":"HR Shinefield","year":"2010","unstructured":"Shinefield HR. Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use. Vaccine. 2010;28:4335\u20139.","journal-title":"Vaccine"},{"key":"3098_CR15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1086\/323342","volume":"184","author":"KK Kamboj","year":"2001","unstructured":"Kamboj KK, King CL, Greenspan NS, Kirchner HL, Schreiber JR. Immunization with Haemophilus influenzae type b-CRM(197) conjugate vaccine elicits a mixed Th1 and Th2 CD(4+) T cell cytokine response that correlates with the isotype of antipolysaccharide antibody. J Infect Dis. 2001;184:931\u20135.","journal-title":"J Infect Dis"},{"key":"3098_CR16","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1182\/blood.V87.9.3877.bloodjournal8793877","volume":"87","author":"C Sgadari","year":"1996","unstructured":"Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein-10. Blood. 1996;87:3877\u201382.","journal-title":"Blood"},{"key":"3098_CR17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.184.3.981","volume":"184","author":"DA Arenberg","year":"1996","unstructured":"Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, et al. Interferon-g-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med. 1996;184:981\u20132.","journal-title":"J Exp Med"},{"key":"3098_CR18","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1016\/S0264-410X(00)00498-9","volume":"19","author":"J Aucouturier","year":"2001","unstructured":"Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine. 2001;19:2666\u201372.","journal-title":"Vaccine"},{"key":"3098_CR19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","volume":"9","author":"P Marrack","year":"2009","unstructured":"Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9:287\u201393.","journal-title":"Nat Rev Immunol"},{"key":"3098_CR20","doi-asserted-by":"crossref","first-page":"e0126334","DOI":"10.1371\/journal.pone.0126334","volume":"10","author":"A Wagner","year":"2015","unstructured":"Wagner A, Schabussova I, Ruttkowski B, Peschke R, Kur J, Kundi M, et al. Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB\/c mice. PLoS One. 2015;10:e0126334.","journal-title":"PLoS One"},{"key":"3098_CR21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/BF00812261","volume":"21","author":"MR Shurin","year":"1999","unstructured":"Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1\/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol. 1999;21:339\u201359.","journal-title":"Springer Semin Immunopathol"},{"key":"3098_CR22","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-10-2907","volume":"71","author":"M Tosolini","year":"2011","unstructured":"Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011;71:1263\u201371.","journal-title":"Cancer Res"},{"key":"3098_CR23","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.4049\/jimmunol.163.12.6448","volume":"163","author":"JM Brewer","year":"1999","unstructured":"Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol. 1999;163:6448\u201354.","journal-title":"J Immunol"},{"key":"3098_CR24","first-page":"779","volume":"138","author":"T Mohan","year":"2013","unstructured":"Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res. 2013;138:779\u201395.","journal-title":"Indian J Med Res"},{"key":"3098_CR25","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","volume":"136","author":"TR Mosmann","year":"1986","unstructured":"Mosmann TR, Cherwinski HM, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136:2348\u201357.","journal-title":"J Immunol"},{"key":"3098_CR26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0167-5699(96)80606-2","volume":"17","author":"TR Mosmann","year":"1996","unstructured":"Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138\u201346.","journal-title":"Immunol Today"},{"key":"3098_CR27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1084\/jem.190.5.617","volume":"190","author":"T Nishimura","year":"1999","unstructured":"Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, et al. Distinct role of antigen-specific T helper type (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med. 1999;190:617\u201327.","journal-title":"J Exp Med"},{"key":"3098_CR28","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","volume":"17","author":"MR Zaidi","year":"2011","unstructured":"Zaidi MR, Merlino G. The Two Faces of Interferon-\u03b3 in cancer. Clin Cancer Res. 2011;17:6118\u201324.","journal-title":"Clin Cancer Res"},{"key":"3098_CR29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-07-1881","volume":"14","author":"GG Kenter","year":"2008","unstructured":"Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Cancer therapy: clinical: phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human Papillomavirus 16 in End-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res. 2008;14:169\u201377.","journal-title":"Clin Cancer Res"},{"key":"3098_CR30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-065X.1999.tb01327.x","volume":"170","author":"DF Tough","year":"1999","unstructured":"Tough DF, Sun S, Zhang X, Sprent J. Stimulation of naive and memory T cells by cytokines. Immunol Rev. 1999;170:39\u201347.","journal-title":"Immunol Rev"},{"key":"3098_CR31","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.4049\/jimmunol.166.10.6007","volume":"166","author":"DF Tough","year":"2001","unstructured":"Tough DF, Zhang X, Sprent J. An IFN\u03b3-dependent pathway controls stimulation of memory phenotype CD81 T cell turnover in vivo by IL-12, IL-18, and IFN\u03b3. J Immunol. 2001;166:6007\u201311.","journal-title":"J Immunol"},{"key":"3098_CR32","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4049\/jimmunol.166.2.1097","volume":"166","author":"G Lertmemongkolchai","year":"2001","unstructured":"Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ. Bystander activation of CD81 T cells contributes to the rapid production of IFN\u03b3 in response to bacterial pathogens. J Immunol. 2001;166:1097\u2013105.","journal-title":"J Immunol"},{"key":"3098_CR33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00262-013-1516-5","volume":"63","author":"V Lennerz","year":"2014","unstructured":"Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, et al. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother. 2014;63:381\u201394.","journal-title":"Cancer Immunol Immunother"},{"key":"3098_CR34","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/cncr.29925","volume":"122","author":"M Reuschenbach","year":"2016","unstructured":"Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Kloor M, Prigge ES, et al. A phase 1\/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers. Cancer. 2016;122:1425\u201333.","journal-title":"Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T04:56:59Z","timestamp":1692680219000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3098-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3098"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3098-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]},"article-number":"118"}}